Target intelligence / Profile preview

Caspase recruitment domain family member 8 (CARD8)

Target
CARD8
Molecular classification
Adaptor protein, Death domain superfamily, Inflammasome component, Caspase recruitment domain (CARD)-containing protein, Signal transduction regulatory protein
01

Overview

Caspase recruitment domain family member 8 (CARD8) is a cytosolic adaptor protein belonging to the death domain superfamily, characterized by the presence of a caspase recruitment domain (CARD) and a FIIND (function to find domain). CARD8 is a key regulator of apoptotic and inflammatory signaling, functioning as an inflammasome sensor, particularly responsive to pathogen and damage-associated signals in human cells. Upon activation, CARD8 undergoes auto-proteolytic cleavage, releasing its C-terminus, which self-oligomerizes to form the CARD8 inflammasome. This complex directly recruits and activates pro-caspase-1, resulting in the cleavage of gasdermin D, initiation of pyroptosis, and secretion of inflammatory cytokines. CARD8 also inhibits NF-kappa-B signaling, playing an anti-inflammatory role. Genetic variants of CARD8 have been associated with increased risk for chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. CARD8 expression is upregulated in certain cancers and is implicated in immune response modulation and cell death regulation.

Other names
CARD8TUCANCARDINALDACARKIAA0955NDPPNDPP1CARD8-CT (C-terminus)CARD8-NT (N-terminus)CARD inhibitor of NF-kappa-B-activating ligandstumor up-regulated CARD-containing antagonist of CASP9
02

Mechanism of action

Direct recruitment and activation of pro-caspase-1, leading to gasdermin-D cleavage and pyroptosis (cell lytic death); Negative regulation of NF-kappa-B, reducing inflammatory signaling

03

Biological functions

ApoptosisInflammasome assemblyImmune responsePyroptosisRegulation of caspase activation (CASP1, CASP9)Negative regulation of NF-kappa-B activationProgrammed cell death
04

Disease associations

CancerChronic inflammationRheumatoid arthritisInflammatory Bowel DiseasePharyngitis
05

Safety considerations

Unintended inflammasome activation may cause severe inflammatory or autoimmune reactionsCARD8 pathway manipulation may involve risks associated with excessive cell death ( pyroptosis) and cytokine release
06

Interacting drugs

Currently, no approved drugs specifically target CARD8 directly; research compounds targeting inflammasome pathways or upstream regulators may affect CARD8 activity.
07

Biomarkers

CARD8 gene polymorphisms (e.g., marker of susceptibility to rheumatoid arthritis)CARD8 protein expression in tumor specimens (marker for some cancers)

Beyond the preview

Go deeper on Caspase recruitment domain family member 8 (CARD8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caspase recruitment domain family member 8 (CARD8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call